NEWS COMMENTARY

Singaporean digital therapeutics startup Biofourmis raises $35 million for chronic disease management

Published:
June 03, 2019
Coverage:
Digital Transformation More...
Activities:
Investment
Very important

Biofourmis has now brought its total investment raised to over $40 million. It also just obtained FDA 510(k) clearance for RhythmAnalytics, a cloud-based software that uses deep learning to extract and interpret more than 15 types of cardiac arrhythmias. This investment round was led by big-name VCs like Sequioa Capital, MassMutual Ventures, and Singapore government-linked investment arm EDBI. Clients looking to partner with digital therapeutics startups should look at examples like Biofourmis. Biofourmis' partnerships with clinical centers in Singapore and Boston allows it to validate its product in Asian and American demographics in parallel, which addresses unique population differences and enables its product to reach a larger market.

For the original news article, click here .


Further Reading

Digital stethoscope company Eko adds $65 million in funding following FDA clearance of its AI algorithms and COVID-19 tailwinds

News Commentary | November 16, 2020

Since Eko's last funding round in 2019, the company has received FDA clearance for its AI algorithms that detect suspected murmurs, the presence of atrial fibrillation (AFib), and normal sinus rhythm. Moreover, the company claims that it's seen a rapid rise in demand for its system due to COVID‑19, ... Not part of subscription

NERv Technology's latest investment round will support the company in its next steps toward clinical trials but with limits

News Commentary | May 07, 2021

NERv Technology, a Canadian medical sensor startup, raised a $2.65 million seed round investment that it plans to use toward seeking regulatory approval, completing clinical trials, and establishing production lines. The company's sensor technology focuses on monitoring postoperative complications, ... Not part of subscription

Cricket Health raises $83.5 million Series B round, seeing continued interest from insurance providers

News Commentary | August 18, 2021

The company develops a patient care platform for chronic kidney disease (CKD). Among the investors are providers Cigna and Blue Shield of California, both of which have strategic partnerships with the company. Cigna reports that since May of 2020, their partnered kidney disease health plan has seen ... Not part of subscription